Tumori Journal – Author's Insight: A phase 2 study of cabozantinib for advanced renal cell carcinoma after immune-checkpoint inhibitors: the BREAKPOINT trial

<p class="MsoNormal"><span lang="EN-GB" style= "color: rgb(0, 0, 0); background: rgb(255, 255, 255);" xml:lang= "EN-GB">In this podcast, Dr Mélanie Claps and Dr Giuseppe Procopio discuss about the results of the Breakpoint Trial: a prospective, multicenter, single arm phase II trial evaluating efficacy and safety of cabozantinib for patients with metastatic renal cell carcinoma progressed after one line of treatment based on immune-checkpoints inhibitors.  </span></p>